American Society of Hirudotherapy

Treatment of cancer-associated thrombosis

Review published in Blood (2013)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewClinical LiteratureDrug DevelopmentLee et al. · Blood, 2013

Abstract

Therapeutic options for the management of venous thromboembolism (VTE) in patients with cancer remain very limited. Although low-molecular-weight heparin monotherapy has been identified as a simple and efficacious regimen compared with an initial parenteral anticoagulant followed by long-term therapy with a vitamin K antagonist, many clinical questions remain unanswered. These include optimal duration of anticoagulant therapy, treatment of recurrent VTE, and the treatment of patients with concurrent bleeding or those with a high risk of bleeding. Treatment recommendations from consensus clinical guidelines are largely based on retrospective reports or extrapolated data from the noncancer population with VTE, as randomized controlled trials focused on cancer-associated thrombosis are sorely lacking. Furthermore, with improvements in imaging technology and extended survival duration of patients with cancer, we are encountering more unique challenges, such as the management of incidental VTE. Clinicians should be aware of the limitations of the novel oral anticoagulants and avoid the use of these agents because of the paucity of evidence in the treatment of cancer-associated thrombosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsHumansNeoplasmsPractice Guidelines as TopicVenous Thrombosis

Summary

This review of cancer-associated venous thromboembolism finds low-molecular-weight heparin monotherapy simple and efficacious, highlights unanswered questions on duration, recurrence and bleeding, and cautions against novel oral anticoagulants given the paucity of evidence.

Context

This review article addresses the management of cancer-associated venous thromboembolism, noting that low-molecular-weight heparin monotherapy remains the mainstay compared with parenteral anticoagulation followed by vitamin K antagonists, while many clinical questions—optimal duration, recurrent VTE treatment, management of patients with bleeding risk—remain unanswered due to a scarcity of randomized controlled trials in cancer populations. The authors caution against use of novel oral anticoagulants in this setting given insufficient evidence. This article addresses antithrombotic pharmacotherapy broadly but contains no reference to leeches, hirudotherapy, or the leech secretome.

Citation

Reference (Vancouver style)

Lee AY, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013;122(14):2310-2317. doi:10.1182/blood-2013-04-460162. PMID: 23843493

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.